Targets › NCBP1
1 program from 1 company in 4 trials: 2 Phase 2, 1 Phase 3, 1 Phase 1; Immunology, Other; next expected readout Dec 2026.
Component of the cap-binding complex (CBC), which binds cotranscriptionally to the 5'-cap of pre-mRNAs and is involved in various processes such as pre-mRNA splicing, translation regulation, nonsense-mediated mRNA decay, RNA-mediated gene silencing (RNAi) by microRNAs (miRNAs) and mRNA export. The CBC complex is involved in mRNA export from the nucleus via its interaction with ALYREF/THOC4/ALY, leading to the…. (UniProt, Q09161)
Open in Phaseline: the race on NCBP1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Abivax | Obefazimod (ABX464) Cap binding complex modulator | NCBP2, NCBP1 | Phase 3 | Ulcerative Colitis; Moderately to Severely Active Crohn Disease; Healthy | Dec 2026 |
Ulcerative Colitis (2) Moderately to Severely Active Crohn Disease (1) Healthy (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.